This page shows the latest Lokelma news and features for those working in and with pharma, biotech and healthcare.
AZ acquired Lokelma ( sodium zirconium cyclosilicate) via a $2.7bn acquisition of ZS Pharma three years ago, but suffered serious setbacks in its approval thanks to manufacturing compliance issues. ... However an initial US black box warning related to
Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.
AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. ... Lokelma (sodium zirconium cyclosilicate or ZS-9) has been cleared by the FDA as
The company has a number of promising new cancer treatments, and has just received FDA approval for the delayed hyperkalaemia drug Lokelma.
AstraZeneca has at long last won EU approval for Lokelma as an oral treatment for high potassium levels, more than a year after it was backed by the EMA’s Committee ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid
However, there’s potential competition on the horizon from AstraZeneca, which has a positive opinion the Committee for Medicinal Products for Human Use (CHMP) for its hyperkalaemia drug Lokelma (sodium zirconium ... This should have put Lokelma on
More from news
Approximately 4 fully matching, plus 3 partially matching documents found.
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....